Multiple myeloma has an incidence rate of 102,000 and death rate of 72,000 people per year worldwide. The incidence varies by ethnicity with highest rates observed in African Americans followed by people from industrialized nations. Consistent risk factors for MM include increasing age, male gender, black race, MGUS, and family history with familial aggregates seen globally. Chromosome abnormalities commonly seen include hyperdiploidy, translocations involving the immunoglobulin heavy chain, monosomy of chromosome 13, gains of chromosome 1q, and deletion of 17p. These chromosome abnormalities have also been observed in Asian and South American countries, although mild variability in frequencies has been seen. The International Staging System (ISS) was first validated in MM patients from North America and Europe and has shown significant correlation to survival in cohorts from South America and Asia. High-dose chemotherapy followed by autologous stem cell transplant (ASCT) and the novel agents, thalidomide, lenalidomide, and bortezomib are recent advances that have improved response rates and survival. The original studies proving efficacy were primarily performed in the United States and European countries. Although, African Americans were seen to be 23% less likely to receive chemotherapy, similar response rates and survival were seen when given equal access to care. Recent data from several countries in South America and Asia have also shown similar advances in response rates and survival to ASCT and novel agents. The parallel improvements signify that monitoring adequate and equal access to care is critically important in order to improve the long term outcome of MM globally.
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Male Female figure 1. Multiple myeloma global age-adjusted incidence rates per 100,000 people for men and women 12 Monoclonal gammopathy of undetermined significance (MGUS) is considered a precursor to MM and is defined as the presence of a monoclonal protein without evidence of organ damage. The prevalence of MGUS also varies by ethnicity with the highest rates seen in African Americans and in Ghanian men. 6, 7 According to studies screening similar age groups, worldwide estimates of the prevalence of MGUS are 5.8% in Ghana, 3.2% in American Caucasians, 2.4% in Japan, and 1.7% in France.
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RIsK fAcToRs
Although consistent differences in incidence and mortality among varying ethnicities have been observed, the etiologies for these patterns are unclear. rates of progression to MM do not appear to be higher. In the Veterans Affairs Hospital study by Landgren et al, similar rates of progression to MM were observed between AA (17%) and Caucasians (15%) by 10 years of follow up. 18 Although there are no confirmed features that determine which patients with MGUS will progress to MM, a stratification model for risk of progression was developed using data from the Mayo Clinic cohort. 19 Increasing M-protein levels were associated with higher risks of progressing to MM by 20 years: 14% for < 0.5mg/dL, 16% for 1.0mg/dL, 25% for 1.5mg/dL, 41% for 2.0mg/dL, 49% for 2.5mg/dL, and 64% for 3.0mg/dL. Patients with either an IgM or IgA isotype were also at higher risk for progressing when compared to patients with the IgG isotype (p=0.001). Patients with an abnormal serum free lightchain ratio had a higher risk of progressing to MM in comparison to patients with a normal ratio (p<0.001). A stratification model using these three risk factors found that patients with all three risk factors had a 58% risk of progression, two risk factors had a 37% risk, one risk factor had a risk of 21%, and patients with none of the risk factors had a 5% risk of progression at 20 years (Table 1 ). Evolving SMM was characterized by a progressive increase in the monoclonal protein with a median time-to-progression (TTP) of 1.3 years while non-evolving SMM had a longer latency period followed by an abrupt progression and median TPP of 3.9 years.
The most frequently staging systems used for MM are the DurieSalmon and International Staging System (ISS) ( Table 4) 52%, 15.1 months for percentages of patients and median overall survival, respectively). 67 Based on this data, it appears that the ISS is applicable to cohorts of patients that were not originally included in the multi-national study for providing prognostic value (Table 5 ).
TheRAPy
The current recommendation for when to initiate therapy is when or- Thalidomide has also been shown to have efficacy in the front-line setting. In an Eastern Cooperative Oncology Group (ECOG) study of 207 newly diagnosed MM patients randomized to either thalidomide/dexamethasone versus dexamethasone, the thalidomide/dexamethasone arm showed significantly higher response rates (63% vs. 41%, p=0.0017) but at a cost of higher toxicity including deep vein thrombus and neuropathy. 87 Another study comparing induction with thalidomide/dexamethasone to vincristine/adriamycin/dexamethasone (VAD) followed by high-dose chemotherapy and ASCT in 203 newly diagnosed MM patients found higher rates of a very good partial response (VGPR) or higher in 24.7% of patients treated with thalidomide/dexamethasone versus 7.3% in the VAD arm. 88 Lenalidomide was developed as an analog to thalidomide with the hopes of reducing therapy-related toxicity. Based on very encouraging results from a Phase I trial showing 71% of patients in the relapsed setting having clinical benefit, lenalidomide was combined with dexamethasone in the front-line setting. 89 In a Phase II study from the Mayo Clinic of newly diagnosed patients with MM treated with lenalidomide and dexamethasone, an objective response rate of 91% was observed. 90 In a phase III ECOG study of 445 newly diagnosed MM patients that were randomized to lenalidomide with either high-dose or low-dose dexamethasone regimens, although higher response rates were seen in the lenalidomide/high-dose dexamethasone arm (82% vs. 70%, respectively), lower rates of Grade 3 or higher toxicity (30% vs. 50%, respectively) and higher rates of overall survival were seen in the lenalidomide/low-dose dexamethasone arm (87% vs. 70% at 2 years follow up, respectively).
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Bortezomib is a proteosome inhibitor whose first Phase II study was in 202 patients from the United States, including 10% African Americans, with relapsed/refractory MM and showed a 35% response rate in heavily pre-treated patients. 92 In the upfront setting, a phase III IFM study of 482 patients with newly diagnosed MM were randomized to either bortezomib/dexamethasone or VAD followed by a second randomization for two more cycles of chemotherapy with dexamethasone, cyclophosphamide, etoposide, and cisplatin and then ASCT versus going directly to ASCT after induction therapy. overall response rate and 23.8% CR rate were observed. 101 The therapeutic impact of high-dose chemotherapy with ASCT appears to have similar benefit in AA as non-AA based on several observational studies. [102] [103] [104] [105] Two large population studies have also evaluated the outcomes of AA patients with MM in the United
States to non-AA. The first by Rohatgi et al found comparable survival benefits to chemotherapy in AA (hazard ratio=0.72, 95% CI 0.61-0.86) as Caucasians (hazard ratio=0.63, 95% CI 0.58-0.67), although AA were 23% less likely to receive chemotherapy. 106 The second population study compared survival rates between AA and non-AA through different eras of therapy. 107 The overall relative survival rate and disease-specific survival rates were higher in AA than Caucasians with MM. However, the Caucasian cohort had significant improvements in their 5-year survival rates through the different eras (26.3% in 1973-1993 era, 30.8% in 1994-1998 era, 35.0%
in 1999-2005 era) whereas the AA cohort did not show a significant with a nonsignificant improvement in disease-free survival (21 vs.
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14 months, p=0.34). 128 Higher rates of grade 3 or 4 infections were seen in the MPT arm, although none were associated with febrile neutropenia and more deaths within the first three months of therapy were seen in the MP arm. The efficacy of these therapies has also been observed in different ethnicities from United States, Europe, Asia, and South America.
However, it is important that toxicities be carefully understood in different races due to potential differences in metabolism. Overall, since several reports have shown parallel improvements in therapeutic responses across the continents, it is of critical importance that future studies of long term outcome of MM patients will be monitoring an adequate and equal access to care in each country. 
